First-Line Alectinib Effective in Asian Patients With ALK-Positive Advanced NSCLC

Alectinib substantially improved outcomes in Asian patients with treatment-naive, ALK-positive NSCLC.

from Latest articles from Cancer Therapy Advisor News https://ift.tt/2qdlTQ9